Prudence is needed when designing a selective TERT-targeting immunotherapy, as pointed out by our previous data about the treatment of prostate tumor-bearing mice with three cycles of ACT with mouse TERT-specific CD8+ T cells that caused a transient B-cell lymphopenia. The gene discussed is CD8A; the disease is lymphopenia.